1. Home
  2. INSM vs L Comparison

INSM vs L Comparison

Compare INSM & L Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • L
  • Stock Information
  • Founded
  • INSM 1988
  • L 1969
  • Country
  • INSM United States
  • L United States
  • Employees
  • INSM N/A
  • L N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • L Property-Casualty Insurers
  • Sector
  • INSM Health Care
  • L Finance
  • Exchange
  • INSM Nasdaq
  • L Nasdaq
  • Market Cap
  • INSM 19.1B
  • L 19.2B
  • IPO Year
  • INSM 2000
  • L N/A
  • Fundamental
  • Price
  • INSM $110.39
  • L $92.53
  • Analyst Decision
  • INSM Strong Buy
  • L
  • Analyst Count
  • INSM 17
  • L 0
  • Target Price
  • INSM $109.20
  • L N/A
  • AVG Volume (30 Days)
  • INSM 2.4M
  • L 804.6K
  • Earning Date
  • INSM 08-07-2025
  • L 08-04-2025
  • Dividend Yield
  • INSM N/A
  • L 0.27%
  • EPS Growth
  • INSM N/A
  • L N/A
  • EPS
  • INSM N/A
  • L 6.28
  • Revenue
  • INSM $381,030,000.00
  • L $18,061,000,000.00
  • Revenue This Year
  • INSM $28.23
  • L N/A
  • Revenue Next Year
  • INSM $119.99
  • L N/A
  • P/E Ratio
  • INSM N/A
  • L $14.39
  • Revenue Growth
  • INSM 20.77
  • L 8.27
  • 52 Week Low
  • INSM $60.40
  • L $75.16
  • 52 Week High
  • INSM $111.25
  • L $93.23
  • Technical
  • Relative Strength Index (RSI)
  • INSM 71.51
  • L 52.77
  • Support Level
  • INSM $101.75
  • L $89.32
  • Resistance Level
  • INSM $105.80
  • L $91.38
  • Average True Range (ATR)
  • INSM 2.78
  • L 1.28
  • MACD
  • INSM -0.08
  • L -0.17
  • Stochastic Oscillator
  • INSM 97.51
  • L 50.90

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About L Loews Corporation

Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.

Share on Social Networks: